Clinical trials: Hemostatic Disorder
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00589563
- Testing
- anti-thymocyte globulin, cyclophosphamide, etoposide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
This is a phase II, multicenter, open label, nonrandomized study to evaluate the efficacy and safety of lenalidomide at a dose of 10 mg/dose in combination with bortezomib at 1.0 mg/m2/dose, pegylated liposomal doxorubicin (PLD)…
- Trial name
- NCT01160484
- Testing
- DVD-R
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This is a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the combination regimen of daratumumab plus durvalumab (D2).
- Trial name
- FUSION-MM-005 (NCT03000452)
- Testing
- DARATUMUMAB, DURVALUMAB
- Where
- 25 sites in United States, Austria and 4 more
- Volunteers
- 18 people
- Sponsor
- Celgene
Skin Neoplasms
Safety and Performance Evaluation of the Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions
This study is designed to monitor patient safety after excision of skin lesions and subsequent application of AC5 topical hemostatic agent and to assess the performance of AC5 for controlling bleeding in skin wounds.
- Trial name
- NCT02704104
- Testing
- AC5 Topical Hemostatic Device
- Where
- Ireland
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Arch Therapeutics
Multiple Myeloma
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
This study was a multi-center, open-label, single-arm, Phase 2 study where newly diagnosed Multiple Myeloma requiring systemic chemotherapy will be eligible for enrollment. A total of 46 subjects were enrolled.
- Trial name
- NCT02969837
- Testing
- Elotuzumab, Carfilzomib, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of Chicago
Multiple Myeloma
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease.
- Trial name
- NCT01090921
- Testing
- Bortezomib
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- Boston VA Research Institute, Inc.
Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
The purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Lymphocytic Leukemia, Chronic
- Trial name
- NCT00241358
- Testing
- AMD3100, Stem Cell Transplant
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Washington University School of Medicine
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
This randomized clinical trial studies standard GVHD prophylaxis with tacrolimus and methotrexate compared to tacrolimus, mycophenolate mofetil and a reduced-dose methotrexate in patients with hematologic malignancies undergoing…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
- Trial name
- NCT01951885
- Testing
- tacrolimus, methotrexate, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
This Phase I/II study is designed to first identify doses of MLN9708 and bendamustine that are associated with an acceptable adverse event profile when delivered together in 28-day cycles.
- Trial name
- NCT02477215
- Testing
- MLN9708, Dexamethasone, Bendamustine (multiple dose levels)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Parameswaran Hari
Multiple Myeloma
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
The primary objective was to determine the maximum tolerated dose of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed multiple myeloma.
- Trial name
- CHAMPION 2 (NCT01980589)
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop plasma cells from growing.
- Trial name
- NCT00564889
- Testing
- cyclophosphamide, dexamethasone, lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of bortezomib in combination with a standard regimen of cyclophosphamide and dexamethasone.
- Trial name
- NCT00833560
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- 34 sites in Germany
- Volunteers
- 401 people
- Sponsor
- Janssen-Cilag G.m.b.H
Multiple Myeloma
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating…
- Trial name
- NCT00091260
- Testing
- dexamethasone, lenalidomide
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Vaishali Sanchorawala
Non-Small Cell Lung Cancer, Multiple Myeloma
Common Safety Follow-up Trial of Tecemotide (L-BLP25)
This is an open-label, common follow-up trial. Subjects who were enrolled in a Merck KGaA, EMD Serono or Merck Serono Japan sponsored trial with tecemotide (L-BLP25) were enrolled in this follow-up trial to continue their…
- Trial name
- NCT01423760
- Testing
- Tecemotide, No intervention
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Immune Thrombocytopenia
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
The primary objective of this study was to assess the long-term safety of lusutrombopag in the treatment of adults with relapsed persistent or chronic ITP with or without prior splenectomy.
- Trial name
- NCT01129024
- Testing
- Lusutrombopag
- Where
- 19 sites in United States
- Volunteers
- 19 people
- Sponsor
- Shionogi
Immune Thrombocytopenic Purpura
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
- Trial name
- ITP (NCT02273960)
- Testing
- BMS-986004 75 mg IV, BMS-986004 225 mg IV, BMS-986004 675 mg IV
- Where
- 20 sites in United States, Australia and 6 more
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Hemophilia B
BAX 326 (rFIX) Continuation Study
The purpose of this BAX 326 Continuation Study is to further investigate incremental recovery over time, the hemostatic efficacy, the safety, immunogenicity, and health-related quality of life (HR QoL) of BAX 326 in previously…
- Trial name
- NCT01286779
- Testing
- BAX 326 (Recombinant factor IX)
- Where
- 42 sites in Argentina, Brazil and 15 more
- Volunteers
- 117 people
- Sponsor
- Baxalta now part of Shire
Multiple Myeloma
Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
This clinical trial is for subjects with multiple myeloma that has returned after treatment (relapsed) or did not respond to prior treatment (refractory). The study is in two parts, Phase I and Phase II.
- Trial name
- Romi Poma (NCT01979276)
- Testing
- Romidepsin, pomalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma and Plasma Cell Neoplasm
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00258206
- Testing
- rituximab, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells.
- Trial name
- NCT00445484
- Testing
- pneumococcal polyvalent vaccine, lenalidomide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.